BiPar Sciences, Inc. has announced the expansion of phase II clinical trial programmes for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past six months, expanding on on-going trials in breast and brain cancer.
The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. Clinicians at Memorial Sloan-Kettering Cancer Center will enrol patients who have a mutation in their BRCA1 or BRCA2 genes.
The details can be read here.
No comments:
Post a Comment